$214 Million is the total value of Prosight Management, LP's 44 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 120.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $17,623,000 | +18.2% | 419,602 | +27.9% | 8.24% | +25.9% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $16,557,000 | +53.9% | 553,100 | +42.3% | 7.74% | +63.9% |
| KURA | Buy | KURA ONCOLOGY INC | $14,428,000 | +1.3% | 1,450,000 | +40.0% | 6.74% | +7.8% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $12,571,000 | – | 140,000 | +100.0% | 5.88% | – |
| QURE | Buy | UNIQURE NV | $11,652,000 | -31.5% | 245,564 | +3.4% | 5.45% | -27.1% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $10,826,000 | -15.8% | 75,000 | +19.2% | 5.06% | -10.4% |
| CUE | Buy | CUE BIOPHARMA INC | $7,834,000 | +258.5% | 552,060 | +301.1% | 3.66% | +281.9% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $7,639,000 | -26.3% | 568,348 | +9.8% | 3.57% | -21.6% |
| TZA | New | DIREXION SHS ETF TRdaily sm cp bear | $7,425,000 | – | 125,000 | +100.0% | 3.47% | – |
| CI | Buy | CIGNA CORP NEW | $6,579,000 | +184.9% | 37,129 | +228.8% | 3.08% | +203.3% |
| CHNG | New | CHANGE HEALTHCARE INC | $5,586,000 | – | 559,125 | +100.0% | 2.61% | – |
| ALBO | Buy | ALBIREO PHARMA INC | $5,409,000 | -13.9% | 330,407 | +33.7% | 2.53% | -8.4% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $5,027,000 | -39.4% | 2,035,340 | +42.5% | 2.35% | -35.5% |
| LHCG | New | LHC GROUP INC | $4,894,000 | – | 34,909 | +100.0% | 2.29% | – |
| AMN | New | AMN HEALTHCARE SVCS INC | $4,825,000 | – | 83,471 | +100.0% | 2.26% | – |
| ZGNX | New | ZOGENIX INC | $4,048,000 | – | 163,708 | +100.0% | 1.89% | – |
| ADMA | New | ADMA BIOLOGICS INC | $3,579,000 | – | 1,242,700 | +100.0% | 1.67% | – |
| PSNL | Buy | PERSONALIS INC | $3,347,000 | -24.5% | 414,740 | +2.0% | 1.56% | -19.6% |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $3,013,000 | – | 104,737 | +100.0% | 1.41% | – |
| EHC | New | ENCOMPASS HEALTH CORP | $3,003,000 | – | 46,900 | +100.0% | 1.40% | – |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $2,171,000 | -27.0% | 672,275 | +8.8% | 1.02% | -22.2% |
| EOLS | Buy | EVOLUS INC | $2,134,000 | -26.0% | 514,206 | +117.0% | 1.00% | -21.2% |
| ESTA | New | ESTABLISHMENT LABS HLDGS INC | $1,830,000 | – | 126,658 | +100.0% | 0.86% | – |
| ABBV | New | ABBVIE INC | $1,221,000 | – | 16,030 | +100.0% | 0.57% | – |
| New | CHANGE HEALTHCARE INCcall | $999,000 | – | 100,000 | +100.0% | 0.47% | – | |
| LGND | New | LIGAND PHARMACEUTICALS INC | $836,000 | – | 11,500 | +100.0% | 0.39% | – |
| HCA | New | HCA HEALTHCARE INC | $829,000 | – | 9,223 | +100.0% | 0.39% | – |
| APEN | Buy | APOLLO ENDOSURGERY INC | $648,000 | +42.7% | 337,262 | +111.7% | 0.30% | +52.3% |
| NSP | New | INSPERITY INC | $481,000 | – | 12,900 | +100.0% | 0.22% | – |
| MITO | New | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $417,000 | – | 336,167 | +100.0% | 0.20% | – |
| New | EVOLUS INCcall | $306,000 | – | 73,700 | +100.0% | 0.14% | – | |
| THC | New | TENET HEALTHCARE CORP | $301,000 | – | 20,918 | +100.0% | 0.14% | – |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $77,000 | -87.5% | 41,592 | +8.1% | 0.04% | -86.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.